Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CI-994 plus Gemcitabine in Advanced Pancreatic Cancer
NCT00004861Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 1999
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in pancreatic cancer (PC) comparing CI-994 + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoint: Overall Survival. Started Oct 1999; status: completed.
02
Drugs
tacedinaline
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00004861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004861.